APNHY (Aspen Pharmacare Holdings) Growth Rank: 2 (As of Sep. 15, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APNHY Aspen Pharmacare Holdings Ltd APNHY
70 GF Score
Price $9.72
GF Value $10.18
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Aspen Pharmacare Holdings Growth Rank?

Aspen Pharmacare Holdings APNHY -0.10% 70 Growth Rank is 2 as of Sep. 15, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates APNHY with a GF Score™ of 70/100 and a GF Value™ of $10.18 (Fairly Valued). The stock has 10 warning signs investors should review.

Aspen Pharmacare Holdings has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Aspen Pharmacare Holdings Growth Rank Related Terms

APNHY vs ZTS, UTHR, VTRS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Growth Rank distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Growth Rank falls into.


APNHY
70GF Score
Aspen Pharmacare Holdings Ltd APNHY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Aspen Pharmacare Holdings (APNHY) has a Growth Rank of 2 as of Sep. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Aspen Pharmacare Holdings and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Aspen Pharmacare Holdings' Growth Rank has ranged from 1.00 to 10.00.
Is Aspen Pharmacare Holdings' Growth Rank too high?
Aspen Pharmacare Holdings' current Growth Rank of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Aspen Pharmacare Holdings has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Growth Rank compare to ZTS and UTHR?
Aspen Pharmacare Holdings' Growth Rank of 2 can be compared against companies in the Drug Manufacturers industry. Historically, Aspen Pharmacare Holdings' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Aspen Pharmacare Holdings and its competitors. Aspen Pharmacare Holdings's current Growth Rank is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Fairly Valued. The stock's GF Value™ is $10.18, compared to a current price of $9.72 — trading 4.5% below its estimated fair value. The current Growth Rank is 2, which is 50% below median its 10-year median of 4.00. Aspen Pharmacare Holdings' overall GF Score™ is 70/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current Growth Rank is 2 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?

Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued. The current stock price of $9.72 is trading 4.5% below its estimated GF Value™ of $10.18. GuruFocus considers Aspen Pharmacare Holdings to be Fairly Valued.

Key valuation signals for APNHY:

  • Growth Rank: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: $10.18 vs. price of $9.72 (4.5% below fair value)
  • GF Score™: 70/100 with 10 warning signs

No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspen Pharmacare Holdings Business Description

Address Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
70GF Score

Get the complete analysis for APNHY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.72
Price
$10.18
GF Value